Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus or Rapamycin Monotherapy in Renal Cancer: Early Pharmacodynamic and Antiangiogenic Responses
2010-022589-29Phase 4Terminated
- Sponsor
- University of Oxford
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of everolimus and sirolimus in renal cell carcinoma (RCC) (2 arms), sponsored by University of Oxford. Primary endpoint: Pharmacodynamic effects on cell signaling and intratumoral blood flow after two weeks of mTOR inhibitor therapy. Started Jan 2011; status: terminated.
02
Drugs
everolimussirolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2010-022589-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022589-29.